Cargando…

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation

Background: CDK 4 and 6 inhibitors (CDK4/6i), which arrest unregulated cancer cell proliferation, show clinical efficacy in breast cancer. Unexpectedly, a patient treated on a CDK4/6i-based trial, as first-line therapy in metastatic breast cancer, developed rapid disease progression following discon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bashour, Sami I., Doostan, Iman, Keyomarsi, Khandan, Valero, Vicente, Ueno, Naoto T., Brown, Powel H., Litton, Jennifer K., Koenig, Kimberly B., Karuturi, Meghan, Abouharb, Sausan, Tripathy, Debasish, Moulder-Thompson, Stacy L., Ibrahim, Nuhad K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559961/ https://www.ncbi.nlm.nih.gov/pubmed/28819400 http://dx.doi.org/10.7150/jca.18196

Ejemplares similares

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
por: Vijayaraghavan, Smruthi, et al.
Publicado: (2017)

Low-molecular-weight cyclin E: the missing link between biology and clinical outcome
por: Akli, Said, et al.
Publicado: (2004)

Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer
por: Abuhadra, Nour, et al.
Publicado: (2022)

Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial
por: Abuhadra, Nour, et al.
Publicado: (2023)

Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer
por: Alexander, Angela, et al.
Publicado: (2017)

PKC iota promotes ovarian tumor progression through deregulation of cyclin E
por: Nanos-Webb, Angela, et al.
Publicado: (2015)

PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens
por: Chen, Hui, et al.
Publicado: (2023)

A Novel Interaction Between HER2/neu and Cyclin E in Breast Cancer
por: Mittendorf, Elizabeth A., et al.
Publicado: (2010)

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
por: Lim, Bora, et al.
Publicado: (2019)

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
por: Le Du, Fanny, et al.
Publicado: (2015)

Leveraging MYC as a therapeutic treatment option for TNBC
por: Carey, Jason P.W., et al.
Publicado: (2018)

Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype
por: Bashour, Sami I., et al.
Publicado: (2020)

LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers
por: Lulla, Amriti R., et al.
Publicado: (2021)

Breaking the cycle: An insight into the role of ERα in eukaryotic cell cycles
por: Moghadam, Sonia Javan, et al.
Publicado: (2011)

Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age
por: Johnston, Simon J., et al.
Publicado: (2020)

The Serine Protease Inhibitor Elafin Maintains Normal Growth Control by Opposing the Mitogenic Effects of Neutrophil Elastase
por: Caruso, Joseph A., et al.
Publicado: (2014)

Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy
por: Weiss, Anna, et al.
Publicado: (2018)

Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration
por: Chen, Xian, et al.
Publicado: (2021)

Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer
por: Mull, Benjamin B., et al.
Publicado: (2020)

Clinical outcomes based on multigene profiling in metastatic breast cancer patients
por: Basho, Reva K., et al.
Publicado: (2016)

Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma
por: Delpech, Yann, et al.
Publicado: (2015)

Challenges and perspective of drug repurposing strategies in early phase clinical trials
por: Kato, Shumei, et al.
Publicado: (2015)

Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases
por: Alhalabi, Omar, et al.
Publicado: (2021)

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
por: Kai, Megumi, et al.
Publicado: (2021)

Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence
por: Caruso, Joseph A, et al.
Publicado: (2014)

Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence
por: Caruso, Joseph A, et al.
Publicado: (2015)

Intestinal perforation as a first presentation of granulomatosis with polyangiitis: unusual case report
por: Khalayli, Naram, et al.
Publicado: (2023)

Targeting the cell cycle for prognosis and therapy of breast cancer
por: Keyomarsi, K, et al.
Publicado: (2005)

Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative
por: Elsayegh, Nisreen, et al.
Publicado: (2015)

Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity
por: Reddy, S M, et al.
Publicado: (2018)

LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients
por: Duong, MyLinh T., et al.
Publicado: (2012)

Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer
por: Hunt, Kelly K, et al.
Publicado: (2013)

PB1961: INVOLVEMENT OF IMMUNITY IN THE CONTINUATION OF TFR AFTER BOSTINIB DISCONTINUATION
por: Fujioka, Yuki, et al.
Publicado: (2023)

The Prognostic Value and Overexpression of Cyclin A Is Correlated with Gene Amplification of both Cyclin A and Cyclin E in Breast Cancer Patient
por: Husdal, A., et al.
Publicado: (2006)

CyclinPred: A SVM-Based Method for Predicting Cyclin Protein Sequences
por: Kalita, Mridul K., et al.
Publicado: (2008)

Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2019)

Ixabepilone development across the breast cancer continuum: a paradigm shift
por: Ibrahim, Nuhad K
Publicado: (2010)

Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer
por: Ibrahim, Nuhad K.
Publicado: (2021)

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
por: Liu, Xuan, et al.
Publicado: (2022)

Parallel cyclin E and cyclin A expression in neoplastic lesions of the uterine cervix
por: Erlandsson, F, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_2oopeo13qrri4al4sn7jg9to18